市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看跌 |
| Biotechnology (全球的) | 混合的 | 看跌 | |
| 股票 | ImmunityBio, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 5.0 |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | -1.0 |
| 技术振荡指标 | -2.5 |
| 平均 | 0.50 |
|
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Growth |
| 内部持股比例 | 74.11% |
| 机构持股比例 | 9.33% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Alphacore Capital Llc | 30 Jun 2025 | 2,974,878 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 24.00 (D. Boral Capital, 971.43%) | 购买 |
| 中 | 16.00 (614.29%) | |
| 低 | 8.00 (HC Wainwright & Co., 257.14%) | 购买 |
| 平均值 | 16.00 (614.29%) | |
| 总计 | 2 购买 | |
| 平均价格@调整类型 | 2.61 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| D. Boral Capital | 19 Aug 2025 | 24.00 (971.43%) | 购买 | 2.28 |
| 14 Aug 2025 | 24.00 (971.43%) | 购买 | 2.71 | |
| HC Wainwright & Co. | 04 Jun 2025 | 8.00 (257.14%) | 购买 | 2.93 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合